Bacterial Pneumonia – Pipeline Review, 2019

Bacterial pneumonia is an inflammation of the lungs due to the bacterial infection caused by bacteria Streptococcus Pneumoniae. According to the American Lung Association, symptoms of bacterial pneumonia include chest pain, shortness of breath, a cough that may produce yellow or green mucus, fever, chills, and tiredness. According to the U.S. Department of Health & Human Service, approximately 1 million people are detected with pneumonia every year.

Antibiotics like amoxicillin, erythromycin, doxycycline, and sulfamethoxazole are used to treat all types of pneumonia. Recently, in March 2018, the U.S. Food and Drug Administration approved a dosage with a combination of avibactam and ceftazidime for the treatment of the ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.

Research institutes and pharmaceutical companies are constantly focusing on studying and developing new options for the treatment or prevention of pneumonia. For instance; AR-301, which is being studied by Aridis Pharmaceuticals, Inc., is currently in phase-3 clinical trials for the study of adjunctive treatment of ventilator-associated pneumonia (VAP) caused due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with S. Aureus infection.

At present more than 80% of the pipeline candidates for Bacterial Pneumonia are in phase 2 and phase 3. Majority of the studies have been sponsored by pharmaceutical companies.

Report Description

The report on ‘Bacterial Pneumonia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bacterial Pneumonia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bacterial Pneumonia.

The report on ‘Bacterial Pneumonia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope 

• A thorough assessment of the pipeline products by areas such as development stage; the route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences.

Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases. 

Reasons to Buy this Report 

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Bacterial Pneumonia
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Bacterial Pneumonia
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary